Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PSA screening and prostate cancer mortality.

Linda Perron1, Lynne Moore, Isabelle Bairati

  • 1Centre de recherche en cancérologie de l'Université Laval, Département de médecine sociale et preventive, Faculté de médecine, Université Laval, Quebec City, Que.

CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|March 20, 2002
PubMed
Summary

Prostate-specific antigen (PSA) screening did not correlate with reduced prostate cancer mortality in Quebec. This study suggests PSA screening is not responsible for observed declines in prostate cancer deaths.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Economic evaluation of deimplementation interventions: a systematic review.

BMJ quality & safety·2026
Same author

Correction: Association between neurofilament light chain concentrations and outcomes in patients with moderate to severe traumatic brain injury: a systematic review and meta-analysis.

Critical care (London, England)·2026
Same author

Association between neurofilament light chain concentrations and outcomes in patients with moderate to severe traumatic brain injury: a systematic review and meta-analysis.

Critical care (London, England)·2026
Same author

An exploratory analysis of plasma biomarkers associated with cerebral amyloid angiopathy.

Neurobiology of aging·2026
Same author

A single-centre assessment of short-term functional outcomes of holmium laser enucleation vs. robot-assisted simple prostatectomy for medium and large-volume benign prostatic hyperplasia.

The French journal of urology·2026
Same author

Excitatory amino acid inhibitors in adults with acute moderate to severe traumatic brain injury: a systematic review and meta-analysis.

BMJ open·2026

Area of Science:

  • Epidemiology
  • Public Health
  • Oncology

Background:

  • Physicians hypothesized prostate-specific antigen (PSA) screening reduced prostate cancer mortality in the late 1990s.
  • This study investigated the link between early 1990s PSA screening-driven incidence changes and subsequent mortality changes.

Purpose of the Study:

  • To test the hypothesis that PSA screening is responsible for the observed reduction in prostate cancer mortality.
  • To assess the correlation between changes in prostate cancer incidence and subsequent changes in prostate cancer mortality.

Main Methods:

  • The adult male population of Quebec (aged 50+) was divided into 15 birth cohorts and 15 regional populations.
  • Changes in prostate cancer incidence (1989-1993) and mortality (1995-1999) were computed for each cohort/region.

Related Experiment Videos

  • Weighted linear regression assessed the correlation between incidence and mortality changes.

    • Main Results:

    • No significant inverse correlation was found between increased prostate cancer incidence and decreased mortality across birth cohorts (r=0.33, p=0.89).
    • Regional analysis also showed no link between higher incidence increases and greater mortality declines (r=0.13, p=0.68).

    Conclusions:

    • The findings suggest that PSA screening was not associated with the decline in prostate cancer mortality in the studied population.
    • Therefore, PSA screening cannot explain the observed reduction in prostate cancer mortality.